---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（201181522240730.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文吡格列酮格列美脲处方资料（仅供参考）

英文药名: SONIAS (Pioglitazone/Glimepiride Tablets)

中文药名: 吡格列酮格列美脲片

药品介绍
成分：盐酸吡格列酮和格列美脲；
 
适应症
盐酸吡格列酮+格列美脲复方片剂用于治疗2型糖尿病。吡格列酮可减小胰岛素抵抗，磺酰脲类药物格列美脲可刺激胰腺产生更多的胰岛素，这两种药的作用互相配合可更好的控制2型糖尿病患者。

Launch of SONIAS® LD and SONIAS® HD in Japan
– Fixed dose combination tablet of ACTOS® and sulfonylurea for treatment of type 2 diabetes –
Osaka, Japan June 6 2011 – Takeda Pharmaceutical Company Limited (“Takeda”) announced today that it launched SONIAS®, a fixed dose combination tablet of ACTOS® (generic name: pioglitazone HCl) and sulfonylurea (generic name: glimepiride) for treatment of type 2 diabetes in Japan.

SONIAS is a tablet taken orally once daily and has two dosage strengths, “SONIAS LD” and “SONIAS HD” which contain 15mg pioglitazone/1mg glimepiride, and 30mg pioglitazone/3mg glimepiride respectively.

ACTOS, which was discovered by Takeda, is in the thiazolidinedione (TZD) class of oral antidiabetic medications and targets insulin resistance, which is a characteristic symptom associated with type 2 diabetes. Sulfonylurea primarily acts on beta cells of the pancreas and increasing the amount of insulin secretion by the pancreas. It is expected that by combining these two medications which have differing mechanisms of action, patients will be able to avoid missing a dose due to the greater ease of administration, thereby allowing patients with type 2 diabetes to better control their blood glucose levels.

“Adding SONIAS to our broad line-up of treatment for type2 diabetes will allow us to offer more appropriate treatment options to each patient,” said Yasuhiko Yamanaka, Director and Senior Vice President of Pharmaceutical Marketing Division. “SONIAS is a fixed dose combination tablet of ACTOS and sulfonylurea, which has been most commonly prescribed as a co-administrative regime in Japan for treatment of type 2 diabetes so that it is expected to contribute to the treatment of many patients with type 2 diabetes.”

Predicted FY2011 sale of ACTOS including SONIAS is ¥44 billion and has been included in the projected consolidated results for FY2011, which was disclosed on May 15, 2011.

About SONIAS

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（201181522240730.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------